Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. develops medical technology for diagnosing and monitoring serious neurological conditions in acute-care settings. Its Ceribell System is a point-of-care electroencephalography, or EEG, platform that combines portable hardware with AI-powered algorithms for rapid brain monitoring in hospitals. The system is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S.
Company updates commonly address quarterly and annual financial results, adoption of the Ceribell System, FDA clearances for the Clarity algorithm and delirium monitoring, and regulatory designations tied to additional neurological indications such as large vessel occlusion stroke. Ceribell also issues announcements on investor conference participation and other public-company communications.
Ceribell (Nasdaq: CBLL) will report its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss results.
Investors can join by phone (domestic: (800) 715-9871; international: (646) 307-1963; access code 1880547) or via a live and archived webcast in the company's Investor Relations website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) reported fourth-quarter and full-year 2025 results, delivering $24.8M revenue in Q4 (+34% YoY) and $89.1M for 2025 (+36% YoY). Gross margin was 87% Q4 and 88% FY. FY operating expenses rose 42% to $136.7M and net loss was $53.4M. Ceribell received multiple FDA clearances including a continuous monitoring solution, neonatal Clarity clearance, and Breakthrough Device designation for LVO stroke detection. Cash and marketable securities totaled $159.3M. 2026 revenue guidance is $111M–$115M (≈25%–29% growth).
Ceribell (Nasdaq: CBLL) will participate in two investor conferences in early March 2026. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 at 1:00 p.m. PST / 4:00 p.m. EST.
CEO Jane Chao, Ph.D., and CFO Scott Blumberg will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 10:50 a.m. PST / 1:50 p.m. EST. Live and archived webcasts will be available in the company's Investor Relations section.
Ceribell (Nasdaq: CBLL) will release fourth quarter and full year 2025 financial results after market close on February 24, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live and archived webcast available in Investor Relations.
The Ceribell System is described as a portable, AI-powered point-of-care EEG platform and is FDA-cleared for detecting seizure and delirium in acute-care settings.
Ceribell (Nasdaq: CBLL) announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation on January 5, 2026 for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution for hospital patients.
The first-in-class monitor uses Ceribell’s existing point-of-care EEG hardware combined with an AI algorithm to interpret EEG signals for early LVO detection, and builds on recent 510(k) clearances for a neonatal seizure algorithm (Nov 2025) and a delirium screening solution (Dec 2025). The designation is supported by validation from prospective, multi-center studies using EEG data and clinical assessments and targets timely detection of in-hospital strokes, a population that represents up to 17% of U.S. strokes.
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co‑founder will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 9:00 am PST / 12:00 pm EST.
A live and archived webcast of the presentation will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) announced FDA 510(k) clearance for its delirium monitoring solution on Dec 9, 2025, the first FDA-cleared device for continuous delirium screening at the bedside. The solution extends the Ceribell System to simultaneously support continuous seizure, electrographic status epilepticus (ESE), and delirium monitoring.
The delirium algorithm was validated in prospective studies of 225 adults in critical care. Ceribell has submitted a NTAP application to CMS to seek additional reimbursement for the new indication.
Ceribell (Nasdaq: CBLL) announced that the FDA granted 510(k) clearance on November 24, 2025 for its next‑generation Clarity algorithm to detect electrographic seizures from pre‑term neonates through adults. This clearance makes the Ceribell System the first and only AI‑powered point‑of‑care EEG cleared to detect seizures across all ages. The clearance was supported by EEG data from more than 700 patients and builds on a prior 510(k) clearance for a neonatal‑optimized headcap. The company positions the technology to enable faster bedside seizure detection in NICUs to reduce delays, transfers, and potential brain injury.
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co-founder will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025.
The presentation is scheduled for 6:10 a.m. PST / 9:10 a.m. EST. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.
The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.